Table 2.
Number and detailed reasons for discontinuation of belimumab treatment
| Author, year | Study design | n | Reasons |
|---|---|---|---|
| Carrion-Barbera, 2019 | CR | 0 | |
| Castillo Dayer, 2019 | CR | 0 | |
| Gimenez, 2019 | CR | 0 | |
| Gonzalez-Echavarri, 2016 | CR | 0 | |
| Husein-El Ahmed, 2014 | CR | 0 | |
| Carbajal, 2017 | CR | 1 | NR |
| Hernandez-Florez, 2015 | PS | 0 | |
| Lorente, 2018 | PS | 0 | |
| Montserrat, 2016 | PS | 0 | |
| Aldasoro, 2018 | RS | 4 | Lack of efficacy (persistence of arthritis) |
| Almanchel, 2014 | RS | 1 | Thrombosis |
| Alonso, 2014 | RS | 3 |
Lack of response (2) Prolonged adverse reactions (neutropenia) (1) |
| Anjo, 2019 | RS | 4 |
Inadequate response (6 months after starting belimumab) with worsening of cutaneous involvement and oral ulcers and maintenance of pleural effusion (n = 3) Development of lupus nephritis class IV (12 months after starting belimumab) (n = 1) |
| Argumanez, 2019 | RS | 4 |
Ineffectiveness (n = 2) Adverse events: neutropenia and urothelial carcinoma (n = 2) |
| Cortes, 2014 | RS | 2 |
Lack of efficacy (n = 1), Pelvic inflammatory disease (n = 1) |
| Navarro, 2019 | RS | 5 |
Peripheral venous insufficiency (n = 1) Pregnancy (n = 1) Itchy skin lesions (n = 1) Uncertain drug allergy (n = 1) Primary pulmonary hypertension (n = 1) |
| Riancho-Zarrabeitia, 2018 | RS | 4 |
Inefficacy (n = 3) Lupus nephritis class IV (n = 1) |
| Moriano, 2018 | RS | 8 |
Inefficacy (n = 5) Pregnancy (n = 1) Worsening proteinuria (n = 1) |
| Brito-Zeron, 2014 | RS | NR | NR |
NR, not reported; CR, case report; RS, retrospective studies; PS, prospective studies